Redcare Pharmacy's Investment Pivot Faces a Competitive Onslaught

Redcare Pharmacy reports 18.3% revenue growth in Q1 2026, driven by a 35% surge in prescription sales, while navigating high investment and new retail competition.

Redcare Pharmacy's first-quarter figures for 2026 reveal a company in transition, delivering robust top-line growth while navigating its most capital-intensive year to date. The online pharmacy group reported preliminary revenue of €848 million, an 18.3% jump that surpassed its own full-year guidance of 13-15% growth. Yet, with profitability targets pushed back and a new management team at the helm, the path to sustainable earnings is under intense scrutiny.

The competitive landscape is shifting rapidly. Traditional drugstore chains are mounting a direct assault on Redcare's digital turf. Rossmann has declared the launch of its own online pharmacy a central project for the year, with operations set to begin from the Netherlands, leveraging an app with approximately 11 million active users. Meanwhile, dm has been active since late 2025 with its "dm-med" platform, selling thousands of over-the-counter products. This pressure has already prompted CEO Olaf Heinrich to revise the OTC segment's growth forecast down from 16% to a range of 8-10%.

Amid this retail offensive, Redcare's prescription drug business stands as a critical fortress. Crucially, Rossmann has confirmed it will not sell prescription medications, leaving Redcare's core market relatively shielded. The company commands a dominant 67% share of the German online prescription market. This strength was evident in Q1, where group-wide prescription revenue surged 35% to €315 million. In Germany alone, Rx sales soared 55% to €168 million, handily beating analyst expectations of €162 million. Even the historically weaker OTC segment showed signs of life, with growth accelerating to 9.7% from 5.4% in the prior quarter.

A potential tailwind is brewing from German health policy. An expert commission for the federal government has recommended raising the statutory co-payment for prescription drugs by 50%. This would increase patient costs from a range of €5-10 to €7.50-15 per prescription. Federal Health Minister Nina Warken has pledged to advance corresponding legislation swiftly. Analysts like Felix Dennl of Bankhaus Metzler see this as a structural advantage for mail-order pharmacies, likely steering price-sensitive consumers toward cheaper online alternatives.

The company's immediate challenge, however, is its own ambitious investment cycle. Redcare has designated 2026 as a peak investment year, with capital expenditure expected to remain high through 2026 before falling below 2% of revenue from 2027 onward. A key project is the new logistics center in Pilsen, Czech Republic, built in just 14 months. The facility, which is already supplying the Austrian market, aims to boost annual shipping capacity by 15 million parcels. This spending has directly impacted margin guidance; management has revised its medium-term margin target from over 8% down to more than 5%.

Leadership is undergoing a simultaneous renewal. Hendrik Krampe officially took over as CFO in December 2025, bringing two decades of e-commerce finance experience, including eight years as Finance Director for Amazon's European marketplace business. His first major report will be the full Q1 statement due on May 6. The supervisory board has also seen a refresh, with Anja Hendel, Max Müller, and Peter Schmid von Linstow joining as three members depart.

For the full year, management reaffirmed its targets: 13-15% revenue growth, German prescription revenue above €670 million, and an adjusted EBITDA margin of at least 2.5%. Analyst sentiment remains cautiously optimistic. Deutsche Bank maintains a Buy rating with a €99 price target, while Jefferies is notably more bullish with a €150 target, citing the company's growing e-prescription market share. Trading at €50.60, the share price has recovered 63% from its March low of €31.00, though it remains about 25% below its year-start level. The upcoming May report will serve as the first real test for the new executive team's strategy amidst fierce competition and heavy investment.